<DOC>
	<DOCNO>NCT02538484</DOCNO>
	<brief_summary>Assess impact dietary omega 3 free fatty acid and/or letrozole obese , postmenopausal breast cancer patient .</brief_summary>
	<brief_title>Impact Omega 3 Fatty Acid Supplementation Aromatase Obese Subjects</brief_title>
	<detailed_description>Prospective , comparative , three arm , short term , non-interventional study correlative biomarker endpoint . Sixty ( 60 ) obese ( â‰¥ 30 BMI ) newly diagnose ER+ postmenopausal breast cancer patient recruit participate short term ( 30 day ) Phase 0 biomarker evaluation study prior surgical resection .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>At least 18 year age . Postmenopausal confirm medical history Ability understand purpose risk study sign write informed consent form approve investigator 's IRB ( Institutional Review Board ) /Ethics Committee . Estrogen receptor positive breast cancer . Body mass index 30 great . Consented tissue collection CTRC ( Cancer Therapy Research Center ) repository 0732 Cachexia Active systemic illness ( infection include viral illness Hepatitis HIV ) Chronic use NSAIDs ( nonsteroidal antiinflammatory drug ) aspirin omega3 free fatty acid supplementation within last 60 day ( defined great equal 7 consecutive day ) Any NSAIDs aspirin omega3 free fatty acid supplementation within last 14 day History medical noncompliance Scheduled date surgical resection would limit amount time take intervention le 21 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>